You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Selective irreversible MAO-B inhibitor. Displays antiParkinsonian activity; exhibits neuroprotective and antiapoptotic activity against several neurotoxins in cell culture.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 267.34. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.74 mL||18.7 mL||37.41 mL|
|5 mM||0.75 mL||3.74 mL||7.48 mL|
|10 mM||0.37 mL||1.87 mL||3.74 mL|
|50 mM||0.07 mL||0.37 mL||0.75 mL|
References are publications that support the biological activity of the product.
Finberg and Youdim (2002) Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, rese. reversal, serotonergic and DArgic behaviours. Neuropharmacology 43 1110 PMID: 12504917
Maruyama et al (2002) The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human DArgic neuroblastoma SH-SY5Y cells. J.Neural Transm. 109 467 PMID: 11956966
Youdim and Weinstock (2002) Molecular basis of neuroprotective activities of rasag. and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell.Mol.Neurobiol. 21 555
If you know of a relevant reference for Rasagiline mesylate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Rasagiline mesylate, Rasagiline mesylate supplier, Rasagiline, mesylate, monoamine, oxidases, mao-b, mao, b, inhibitors, inhibits, selective, antiparkinsons, antiparkinsonian, parkinson's, parkinsons, Monoamine, Oxidase, Adrenergic, Related, Compounds, Dopaminergic-Related, 5-HT-Related, 5-HT3, Receptors, 4308, Tocris Bioscience
Citations for Rasagiline mesylate
Citations are publications that use Tocris products.
Currently there are no citations for Rasagiline mesylate. Do you know of a great paper that uses Rasagiline mesylate from Tocris? Please let us know.
Reviews for Rasagiline mesylate
There are currently no reviews for this product. Be the first to review Rasagiline mesylate and earn rewards!
Have you used Rasagiline mesylate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.